12/19
09:58 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $19.00. They now have an "overweight" rating on the stock.
12/13
08:05 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
12/12
06:13 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
12/12
08:55 am
itos
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Medium
Report
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
11/26
07:00 am
itos
iTeos to Participate in Upcoming Investor Conferences
Low
Report
iTeos to Participate in Upcoming Investor Conferences
11/15
09:09 am
itos
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/15
08:02 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
11/13
12:45 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
11/12
07:00 am
itos
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/24
07:00 am
itos
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Low
Report
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress